Aicar Tablets, with its core component AICAR (5-aminoimidazole-4-formamide riboside), is mainly used as a research reagent for cell metabolism studies. Its commercial products are usually provided in powder form, and the purity standard is generally ≥98% (HPLC detection). In scientific research experiments, the concentration and dosage of AICAR will be adjusted according to the specific experimental purpose and cell type.
As AICAR is mainly used as a research reagent, the assessment of its safety and efficacy in human clinical applications remains limited. Therefore, when conducting scientific research experiments with AICAR, it is necessary to strictly abide by laboratory safety regulations to ensure the safety of laboratory personnel. When preparing AICAR solutions, it is recommended to select appropriate solvents (such as DMSO, water, etc.) based on experimental requirements, and pay attention to the stability and service life of the solution.
|
|
|
Aicar Powder COA
Epigenetic regulation
The core component of Aicar Tablets, AICAR (5-aminoimidazole-4-formamide ribonucleoside), initiates multi-dimensional regulation at the epigenetic level by activating the AMPK signaling pathway. Its mechanism of action involves key epigenetic processes such as DNA methylation, histone modification, non-coding RNA expression, and chromatin remodeling.
Dynamic Regulation of DNA Methylation
AICAR treatment significantly reduced the whole-genome DNA methylation level (5-methylcytosine, 5mC) of J1 mouse embryonic stem cells (ES cells), while maintaining the DNA hydroxymethylation level (5-hydroxymethylcytosine, 5hmC) unchanged. This selective demethylation is achieved by inhibiting the activity of DNA methyltransferase (DNMT), especially by down-regulating the expression of DNMT3a and DNMT3b. For instance, in the RA-induced ES cell differentiation model, AICAR can antagonize the increase in DNA methylation levels during the differentiation process, maintaining the hypomethylation state of the promoter regions of stem genes (such as Nanog and Oct4), thereby ensuring their continuous expression.
Synergistic Remodeling of histone Modifications
AICAR regulates the expression and activity of histone modification enzymes through AMPK-dependent pathways:
Histone acetylation
It inhibits the activity of histone deacetylase (HDAC), leading to a down-regulation of histone 3 lysine acetylation at position 9 (H3K9Ac), while promoting the activity of histone acetyltransferase (HAT) and enhancing the deposition of activating markers such as H3K27Ac.
Histone methylation
By activating the BMP pathway, it inhibits the expression of histone methyltransferase EZH2, reduces the inhibitory marker of lysine trimethylation at position 27 of histone 3 (H3K27me3), and simultaneously upregulates activating markers such as H3K4me3, forming a "dual-valve" regulatory mechanism.
Chromatin remodeling
AICAR treatment led to the upregulation of the expression of the SWI/SNF complex subunit Smarca2 in ES cells, promoting the formation of chromatin open structures and enhancing the accessibility of stemness genes.
Differentiated Expression of Non-coding Rnas
AICAR significantly affects the expression profiles of miRNA and long non-coding RNA (lincRNA) :
miRNA regulatory network: Up-regulates the expression of mirnas related to pluripotency maintenance (such as the miR-290 family), while down-regulates mirnas related to differentiation (such as miR-134, miR-302). For example, the expression of miR-134 increased during RA-induced differentiation, while AICAR treatment significantly down-regulated its expression, and the expressions of its target genes Nanog and Sox2 were correspondingly up-regulated.
Lincrna-mediated regulation: AICAR promotes the expression of lincRNA-RoR. This molecule inhibits the silencing of differentiated genes by binding to heterochromatin protein 1 (HP1), while recruiting Polycomb inhibitory complex 2 (PRC2) to maintain the activation state of stem genes.
Cross-dialogue of Epigenetic Pathways
AICAR antagonizes RA-induced ES cell differentiation by activating the BMP pathway, and the mechanism involves the synergistic regulation of epigenetic pathways:
BMP signal activation: AICAR upregulates the expression of BMP2, BMP4 and their downstream regulatory genes Ids and Coch, while inhibiting the down-regulation of these gene expressions induced by RA.
Formation of epigenetic barrier: activation of BMP pathway leads to smad1/5/9 phosphorylation, forms complexes with histone modifying enzymes (such as P300 and setd7), deposits activated histone markers (h3k4me3 and h3k27ac) in the promoter region of dry gene, and repels PRC2 complex to prevent the deposition of H3K27me3.
Epigenetic Effects of Preclinical Models
In myocardial ischemia-reperfusion injury models, AICAR exerts cardiac protective effects through epigenetic regulation:
DNA methylation and gene expression
Reduce the DNA methylation level in the promoter regions of pro-inflammatory factors (such as TNF-α and IL-6) in cardiomyocytes and enhance their transcriptional activity.
Histone modification and metabolic reprogramming
Up-regulating the H3K27ac level in the promoter region of the PGC-1α gene promotes mitochondrial biosynthesis and fatty acid oxidation, and improves energy metabolism.
Mitochondrial biogenesis
Mitochondria, as the "energy factory" of cells, their functional decline is closely related to aging, metabolic diseases and neurodegenerative diseases. The core component of Aicar Tablets, AICAR (5-aminoimidazole-4-formamide ribonucleoside), becomes a key molecule regulating mitochondrial biogenesis by activating the AMPK signaling pathway. Its mechanism of action not only involves an increase in mitochondrial numbers, but also covers functional remodeling and heterogeneous regulation, providing new strategies for anti-aging and disease treatment.
AMPK Activation: The core switch of mitochondrial biogenesis
AICAR activates the AMPK signaling pathway by simulating the direct binding of AMP molecules to the γ subunit of AMPK, triggering conformational changes in the kinase domain. This process does not rely on changes in the AMP/ATP ratio within the cell and can still function even when there is sufficient energy. For instance, in the myocardium of patients with tetralogy of Fallot (TOF), hypoxia upregulates PGC-1α expression through an AMPK-dependent pathway, significantly increasing mitochondrial quantity and DNA copy number, suggesting that AICAR may promote mitochondrial biogenesis through a similar mechanism.
After AMPK activation, it enhances the transcriptional co-activation function of PGC-1α by phosphorylating the Thr177 and Ser538 sites. PGC-1α, as a core regulatory factor of mitochondrial biogenesis, can activate downstream factors such as NRF1/2 and TFAM, driving mitochondrial DNA replication, transcription and the synthesis of respiratory chain complexes. In skeletal muscle, AICAR treatment upregulates PGC-1α expression, enhances mitochondrial oxidative phosphorylation ability, increases ATP production, and simultaneously reduces oxidative stress levels.
Multi-dimensional Regulatory Network of Mitochondrial Biogenesis
The synergistic improvement in the quantity and quality of mitochondria
AICAR not only promotes mitochondrial proliferation but also achieves quality remodeling by regulating mitochondrial dynamics. AMPK phosphorylates the Ser155 and Ser173 sites of mitochondrial fission factor MFF, promoting the recruitment of DRP1 to the outer mitochondrial membrane and driving mitochondrial division. This process works in coordination with lipid transport at the mitochondrial-endoplasmic reticulum contact points (MERCs) to ensure that newly split mitochondria have a complete membrane structure. Meanwhile, AMPK activates the autophagy pathway, eliminates dysfunctional mitochondria, and maintains the health of the mitochondrial population.
Metabolic reprogramming and functional optimization
AICAR inhibits acetyl-CoA carboxylase (ACC) through AMPK, reduces the inhibition of CPT1 by malonyl-CoA, and promotes the β -oxidation of fatty acids. In the liver, this mechanism alleviates insulin resistance caused by lipid accumulation; In myocardial ischemia-reperfusion models, AICAR reduces lactic acid accumulation and the risk of acidosis by enhancing fatty acid oxidation and decreasing glucose-dependent ATP production. In addition, AMPK activates the expression of the IV subunit COX4I2 of the electron transport chain complex, optimizing mitochondrial respiratory efficiency.
Mitochondrial DNA repair and stability maintenance
AICAR activates DNA repair enzymes OGG1 and MUTYH to repair 8-oxy-guanine damage in mitochondrial DNA (mtDNA) and reduce mutation accumulation. In neural stem cells, AICAR upregulates mitochondrial single-stranded binding protein (SSBP1) through an AMPK-dependent pathway, enhancing the fidelity of mtDNA replication. This mechanism is crucial for maintaining the mitochondrial function of neurons, as the accumulation of mtDNA mutations is closely related to neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Mitochondrial Heterogeneity: A Scientific Paradigm Beyond Quantity
Traditional research emphasizes that "mitochondrial biogenesis is beneficial", but single-cell sequencing technology reveals that the significance of mitochondrial heterogeneity far exceeds quantity:
Functional division of labor
In skeletal muscle, the mitochondria between muscle fibrils are responsible for the supply of contractile energy, while the mitochondria under the muscle membrane maintain membrane potential and cytoplasmic homeostasis. After acute exercise, the distribution density of mitochondria among myofibrils decreases, suggesting functional specific regulation.
Pathological contradiction
In the fatty liver model, although exercise promotes mitochondrial proliferation, the increase in ATP production may support fat synthesis rather than reduce accumulation. AICAR may preferentially enhance mitochondrial function related to antioxidant and fatty acid oxidation by regulating mitochondrial heterogeneity.
Dynamic regulatory requirements
The type of mitochondria needs to match the ATP requirements. For instance, in brown adipocytes, the perilipid droplet mitochondria (PDM) utilize ATP to synthesize triglycerides, while the cytoplasmic mitochondria (CM) carry out β -oxidation. Although their functions are opposite, they work together to maintain lipid metabolism balance.
Clinical Application and Future Direction
AICAR delays aging-related phenotypes by enhancing mitochondrial biogenesis and function. In the elderly mouse model, AICAR treatment increased the mitochondrial density of skeletal muscle, enhanced exercise endurance, and simultaneously reduced liver lipid deposition and insulin resistance. In addition, the AMPK-PGC-1α pathway activated by AICAR can improve mitochondrial dysfunction in diabetic cardiomyopathy.
In Alzheimer's disease models, AICAR improves synaptic plasticity and memory formation by enhancing the mitochondrial MCU function in the hippocampal CA2 region. The absence of MCU leads to dysfunction of the outermost synaptic layer, while AICAR can restore calcium flow and mitochondrial membrane potential, reducing neuronal death. In addition, AICAR inhibits the activation of NLRP3 inflammasome, reduces neuroinflammation, and provides potential therapeutic strategies for neurological disorders such as autism spectrum disorder.
Future research should focus on the regulation of mitochondrial heterogeneity and develop intervention measures targeting specific mitochondrial subgroups. For instance, by integrating electron microscopy and artificial intelligence technology, a functional map of mitochondria within cells can be drawn, guiding the combined use of AICAR with antioxidants, mitochondrial autophagy inducers, etc., to collaboratively optimize mitochondrial quality control.
Conclusion
Aicar Tablets promote mitochondrial biogenesis through an AMPK-dependent pathway while achieving synergistic regulation of quantity, quality and heterogeneity. This mechanism not only provides new targets for anti-aging and metabolic disease treatment, but also promotes the transformation of the scientific paradigm from "an increase in mitochondria is beneficial" to "functional adaptation regulation". With a deeper understanding of mitochondrial heterogeneity, AICAR is expected to play a greater role in the field of precision medicine and open a new chapter of health and longevity.
Hot Tags: aicar tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale